Cargando…

Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy

For decades, macrocyclic compounds have been widely applied in various fields owing to essential physicochemical properties such as their rigid cyclic structures, geometric dimensions (diameter and height), hydrophobic cavity, and hydrophilic interface. This review is an attempt to summarize various...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Hongzhen, Wang, Jianwei, Li, Zhongbao, Tang, Guping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539895/
https://www.ncbi.nlm.nih.gov/pubmed/31035393
http://dx.doi.org/10.3390/ijms20092097
_version_ 1783422497216004096
author Bai, Hongzhen
Wang, Jianwei
Li, Zhongbao
Tang, Guping
author_facet Bai, Hongzhen
Wang, Jianwei
Li, Zhongbao
Tang, Guping
author_sort Bai, Hongzhen
collection PubMed
description For decades, macrocyclic compounds have been widely applied in various fields owing to essential physicochemical properties such as their rigid cyclic structures, geometric dimensions (diameter and height), hydrophobic cavity, and hydrophilic interface. This review is an attempt to summarize various research accomplishments involving macrocyclic compounds for drug and gene delivery in immune-modulating therapies: the structures and benefits of main host molecules, their mechanisms regulating the immune system from cell uptake to activation of dendritic cells and T helper lymphocytes, as well as their potential immunotherapy for different diseases. Macrocyclic compounds including cucurbiturils (CBs), calixarenes, pillararenes, cyclodextrins (CyDs), macrocyclic peptides and metallo-supramolecular compounds, have their own unique physicochemical properties and functional derivatizations that enable to improve the biocompatibility, responsiveness to stimuli, and effectiveness of immune-modulating therapy. Based on abundant clarifications of the biological immunity mechanisms, representative constructions of macrocyclic compounds for immune therapies have been conducted for the investigation of treatment of different diseases including cancer, atherosclerosis, Niemann-Pick type C1 disease (NPC1), diabetes, and inflammations. Although there are critical challenges that remain to be conquered, we believe the future of macrocyclic compounds in the immune-modulating therapy must be bright.
format Online
Article
Text
id pubmed-6539895
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65398952019-06-04 Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy Bai, Hongzhen Wang, Jianwei Li, Zhongbao Tang, Guping Int J Mol Sci Review For decades, macrocyclic compounds have been widely applied in various fields owing to essential physicochemical properties such as their rigid cyclic structures, geometric dimensions (diameter and height), hydrophobic cavity, and hydrophilic interface. This review is an attempt to summarize various research accomplishments involving macrocyclic compounds for drug and gene delivery in immune-modulating therapies: the structures and benefits of main host molecules, their mechanisms regulating the immune system from cell uptake to activation of dendritic cells and T helper lymphocytes, as well as their potential immunotherapy for different diseases. Macrocyclic compounds including cucurbiturils (CBs), calixarenes, pillararenes, cyclodextrins (CyDs), macrocyclic peptides and metallo-supramolecular compounds, have their own unique physicochemical properties and functional derivatizations that enable to improve the biocompatibility, responsiveness to stimuli, and effectiveness of immune-modulating therapy. Based on abundant clarifications of the biological immunity mechanisms, representative constructions of macrocyclic compounds for immune therapies have been conducted for the investigation of treatment of different diseases including cancer, atherosclerosis, Niemann-Pick type C1 disease (NPC1), diabetes, and inflammations. Although there are critical challenges that remain to be conquered, we believe the future of macrocyclic compounds in the immune-modulating therapy must be bright. MDPI 2019-04-28 /pmc/articles/PMC6539895/ /pubmed/31035393 http://dx.doi.org/10.3390/ijms20092097 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bai, Hongzhen
Wang, Jianwei
Li, Zhongbao
Tang, Guping
Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy
title Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy
title_full Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy
title_fullStr Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy
title_full_unstemmed Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy
title_short Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy
title_sort macrocyclic compounds for drug and gene delivery in immune-modulating therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539895/
https://www.ncbi.nlm.nih.gov/pubmed/31035393
http://dx.doi.org/10.3390/ijms20092097
work_keys_str_mv AT baihongzhen macrocycliccompoundsfordrugandgenedeliveryinimmunemodulatingtherapy
AT wangjianwei macrocycliccompoundsfordrugandgenedeliveryinimmunemodulatingtherapy
AT lizhongbao macrocycliccompoundsfordrugandgenedeliveryinimmunemodulatingtherapy
AT tangguping macrocycliccompoundsfordrugandgenedeliveryinimmunemodulatingtherapy